We are live on ! Find out more
ENZ

Enzo Biochem, Inc.

Delisted

ENZ was delisted on the 17th of April, 2025.

111 hedge funds and large institutions have $121M invested in Enzo Biochem, Inc. in 2016 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 38 increasing their positions, 32 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

831% more call options, than puts

Call options by funds: $512K | Put options by funds: $55K

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

19% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 32

7% more funds holding

Funds holding: 104111 (+7)

18% less capital invested

Capital invested by funds: $147M → $121M (-$25.8M)

100% less funds holding in top 10

Funds holding in top 10: 20 (-2)

Holders
111
Holders Change
+7
Holders Change %
+6.73%
% of All Funds
2.96%
Holding in Top 10
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
New
18
Increased
38
Reduced
32
Closed
11
Calls
$512K
Puts
$55K
Net Calls
+$457K
Net Calls Change
-$110K
Name Holding Trade Value Shares
Change
Change in
Stake
EEG
76
E.E. Geduld
$76K -$59.7K -10,000 -40%
Walleye Trading
77
Walleye Trading
New York
$73K -$132K -22,100 -61%
MCM
78
Maple Capital Management
Vermont
$71K
Wells Fargo
79
Wells Fargo
California
$71K
GC
80
Guggenheim Capital
Illinois
$68K +$48 +8 +0.1%
T. Rowe Price Associates
81
T. Rowe Price Associates
Maryland
$67K +$926 +155 +1%
CCB
82
Cutter & Co Brokerage
Missouri
$66K -$1.26K -211 -2%
CA
83
Corrado Advisors
New Jersey
$66K +$77.1K +12,915 New
PAM
84
Panagora Asset Management
Massachusetts
$64K -$29.2K -4,896 -28%
TC
85
TFS Capital
Pennsylvania
$57K -$829K -138,750 -92%
BlackRock
86
BlackRock
New York
$55K +$2.97K +497 +5%
SG Americas Securities
87
SG Americas Securities
New York
$52K +$60.8K +10,183 New
Fuller & Thaler Asset Management
88
Fuller & Thaler Asset Management
California
$47K
Bank of America
89
Bank of America
North Carolina
$43K +$10.1K +1,699 +25%
PCM
90
Prelude Capital Management
New York
$36K -$36.4K -6,100 -46%
Legal & General Group
91
Legal & General Group
United Kingdom
$34K
SEI Investments
92
SEI Investments
Pennsylvania
$23K +$7.2K +1,205 +37%
LTFS
93
Ladenburg Thalmann Financial Services
Florida
$21K
IA
94
IFP Advisors
Florida
$20K +$23.9K +4,000 New
Royal Bank of Canada
95
Royal Bank of Canada
Ontario, Canada
$15K +$17.9K +3,000 New
BNP Paribas Financial Markets
96
BNP Paribas Financial Markets
France
$15K +$8.18K +1,369 +87%
ASN
97
Advisory Services Network
Georgia
$14K
Federated Hermes
98
Federated Hermes
Pennsylvania
$10K +$1.59K +267 +16%
VCM
99
Versant Capital Management
Arizona
$8K +$143 +24 +1%
TRCT
100
Tower Research Capital (TRC)
New York
$7K +$8.52K +1,426 New

ENZ Hedge Fund Activity: Q3 2016 in Review

111 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q3 2016, worth a combined $121M — down 18% from $147M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ENZ positions and 11 closed out — a net gain of 7 holders — while 38 added to existing stakes and 32 trimmed.

The largest buyer was Globeflex Capital, opening a new position worth an estimated $1.35M. The largest seller was Kopp Investment Advisors, cutting an estimated $2.7M.

  • 111 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q3 2016, up from 104 in Q2 2016.
  • Funds reported $121M of Enzo Biochem, Inc. stock for Q3 2016, down 18% quarter-over-quarter.
  • 18 funds opened new Enzo Biochem, Inc. positions in Q3 2016 and 11 closed out, a net change of +7 holders.
  • The largest Enzo Biochem, Inc. buyer in Q3 2016 was Globeflex Capital, an estimated $1.35M added.
  • The largest Enzo Biochem, Inc. seller in Q3 2016 was Kopp Investment Advisors, an estimated $2.7M sold.

Based on aggregated 13F filings for Q3 2016.